ClinicalTrials.gg
Not yet recruitingNCT07646210Updated Nov 10, 2026

HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery

A Phase 1/2 interventional study of HiCM-188 Cells in Advanced Heart Failure and Ischemic Heart Failure, sponsored by HELP Therapeutics, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by HELP Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Updated Nov 10, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
1,345th of 1,601
12 · median 65
Started
2027
with 10 others
Phase 1/2
56 of 2,157
5 open now
Primary completion
2028-02
later than 293 of 436 live
Registered
2,125th of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 1,345th largest by planned enrollment of the 1,601 interventional ones that give a count, is one of 11 that started in 2027, is one of 56 in phase 1/2, reaches primary completion later than 293 of the 436 other live ones, and was the 2,125th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

This clinical study will evaluate the safety and tolerability of HiCM-188, an investigational allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocyte therapy, in adults with advanced heart failure who are undergoing coronary artery bypass grafting (CABG) surgery.

Participants who meet the study eligibility criteria will receive a single dose intramyocardial injection of HiCM-188 during CABG surgery. The study will evaluate two dose levels of HiCM-188 using an open-label dose-escalation design. Participants will be followed for up to 12 months after treatment to monitor safety and preliminary signs of clinical effect.

Read the detailed description

This is a Phase I/IIa, open-label, dose-escalation study of HiCM-188 in adult participants with advanced heart failure. HiCM-188 is an investigational cell therapy product consisting of allogeneic human iPSC-derived cardiomyocytes intended for intramyocardial administration.

Eligible participants will receive HiCM-188 during coronary artery bypass grafting (CABG) surgery. The study uses a 3+3 dose-escalation design to evaluate two dose levels of HiCM-188: 0.5 × 10\^8 cells and 1.5 × 10\^8 cells. The primary objective is to evaluate the safety and tolerability of intramyocardial injection of HiCM-188. Secondary objectives include evaluation of preliminary efficacy based on cardiac function, myocardial perfusion, exercise capacity, NYHA functional classification, quality of life, and major adverse cardiac events.

Participants will be monitored during the in-hospital period after CABG surgery and HiCM-188 administration, and then followed for up to 12 months after treatment.

03

Conditions studied

  • Advanced Heart Failure
  • Ischemic Heart Failure

Browse trials for

Keywords

  • HiCM-188
  • iPSC-derived cardiomyocytes
  • Allogeneic cell therapy
  • Advanced heart failure
  • Ischemic heart failure
  • Intramyocardial injection
  • Coronary artery bypass grafting
  • CABG
  • Dose escalation
  • NYHA Class III-IVa
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to sign and comply with the study protocol
  • 18 to 75 years old at the time of signing informed consent
  • Advanced heart failure patients with (NYHA) class III to IVa despite receiving guideline-directed medical therapy (GDMT)
  • Patients with an indication for coronary artery bypass grafting (CABG) per 2011 ACCF/AHA Guideline meeting a Class of Recommendation (COR) of Class I or Class IIa
  • Minimum left ventricular wall thickness of ≥ 8 mm in the areas of injection, as confirmed on the screening echocardiogram (ECHO) or cardiac MRI
  • (LVEF) of 20% to 45%, as confirmed on the screening echocardiogram (ECHO) or cardiac MRI
  • Other criteria apply. Please contact the investigator for more information.

Exclusion criteria

Exclusion Criteria:

  • Viral myocarditis
  • Amyloidosis
  • Pericardial disorders or pericarditis
  • Left ventricular aneurysm or thrombus, except a small laminar thrombus at the site of previous myocardial infarction (MI) in a different area
  • Primary significant organic valvular heart disease, with specified dimensions
  • Untreated congenital heart disease
  • Complete atrioventricular (AV) conduction block
  • History of left ventricular assist device surgery
  • Other criteria apply. Please contact the investigator for more information.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    HiCM-188 Low Dose

    Participants in this arm will receive a single low dose of HiCM-188, 0.5 × 10\^8 cells, administered by intramyocardial injection during coronary artery bypass grafting (CABG) surgery.

    Drug: HiCM-188 Cells

  • Experimental
    HiCM-188 High Dose

    Participants in this arm will receive a single high dose of HiCM-188, 1.5 × 10\^8 cells, administered by intramyocardial injection during coronary artery bypass grafting (CABG) surgery.

    Drug: HiCM-188 Cells

Interventions

  • HiCM-188 is an investigational allogeneic human induced pluripotent stem cell (iPSC)-derived cardiomyocyte therapy administered as intramyocardial injection during CABG surgery.

06

What researchers measure

Primary outcomes

  1. Incidence of Serious Adverse Events

    Incidence of serious adverse events (SAEs) at 12 months post-transplant

    Time frame: Up to 12 months post-transplant

Secondary outcomes

  1. Change From Baseline in Left Ventricular Ejection Fraction by Cardiac MRI

    Change from baseline in left ventricular ejection fraction (LVEF, %) assessed by cardiac magnetic resonance imaging (MRI). Echocardiogram may be used as an alternative if cardiac MRI is not medically appropriate or per institutional practice.

    Time frame: Baseline, 6 months, and 12 months

  2. Change From Baseline in Left Ventricular End-Diastolic Volume by Cardiac MRI

    Change from baseline in left ventricular end-diastolic volume (LVEDV, mL) assessed by cardiac MRI. Echocardiogram may be used as an alternative if cardiac MRI is not medically appropriate or per institutional practice.

    Time frame: Baseline, 6 months, and 12 months

  3. Change From Baseline in Left Ventricular End-Systolic Volume by Cardiac MRI

    Change from baseline in left ventricular end-systolic volume (LVESV, mL) assessed by cardiac MRI. Echocardiogram may be used as an alternative if cardiac MRI is not medically appropriate or per institutional practice.

    Time frame: Baseline, 6 months, and 12 months

  4. Change From Baseline in Infarct Size by Cardiac MRI

    Change from baseline in myocardial infarct size assessed by cardiac MRI.

    Time frame: Baseline, 6 months, and 12 months

  5. Change From Baseline in Myocardial Tissue Perfusion by PET/CT or SPECT

    Change from baseline in myocardial tissue perfusion assessed by positron emission tomography/computed tomography (PET/CT) or single-photon emission computed tomography (SPECT).

    Time frame: Baseline, 6 months, and 12 months

  6. Change From Baseline in 6-Minute Walk Distance

    Change from baseline in exercise capacity as assessed by the 6-minute walk distance (6MWD). The 6-Minute Walk Distance is measured as the distance walked in 6 minutes, with longer distances reflecting better functional exercise capacity.

    Time frame: Baseline, 6 months, and 12 months

  7. Change From Baseline in New York Heart Association Functional Classification

    Change from baseline in New York Heart Association (NYHA) functional classification. The New York Heart Association Functional Classification ranges from Class I to Class IV, with higher classes reflecting more severe limitation of physical activity and worse heart failure symptoms.

    Time frame: Baseline, 6 months, and 12 months

  8. Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score

    Change from baseline in quality of life as measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The Minnesota Living With Heart Failure Questionnaire score ranges from 0 to 105, with higher scores reflecting worse heart failure-related quality of life.

    Time frame: Baseline, 6 months, and 12 months

  9. Incidence of Major Adverse Cardiac Events

    Incidence of major adverse cardiac events (MACE) during the study follow-up period.

    Time frame: Up to 12 months post-transplant

07

Study locations

1 site
  • The Texas Heart Institute at Baylor College of Medicine
    Houston, Texas 77030, United States
    • Emerson Perin · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Feb 2028, 12 months later.

Of 43 phase 1/2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 12 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Sep 2026 → Feb 2027, primary completion May 2028 → Feb 2028 and completion May 2028 → Feb 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 12, 2026
StartEst.
Feb 2027was Sep 2026
Primary completionEst.
Feb 2028was May 2028
CompletionEst.
Feb 2029was May 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Feb 2027
Nov 10, 2026
Primary completion
May 2028→Feb 2028
Nov 10, 2026
Study completion
May 2028→Feb 2029
Nov 10, 2026
Contact
Study contact's phone or email changed: A•••@helptx.com.cn→a•••@helptherapeutics.com. See the current contact
Nov 10, 2026
Sponsor
HELP Therapeutics Co., Ltd.→HELP Therapeutics, Inc.
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Start date Sep 2026→Feb 2027
    Primary completion May 2028→Feb 2028
    Study completion May 2028→Feb 2029
    Sponsor HELP Therapeutics Co., Ltd.→HELP Therapeutics, Inc.
    Contact Study contact's phone or email changed: A•••@helptx.com.cn→a•••@helptherapeutics.com. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07646210
Lead sponsor
HELP Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Feb 2027 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Alex Zhang
Contact
alex.zhang@helptherapeutics.com
+1 650 504 5586

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HICM-188

Start the discussion